Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TS ID 11810Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer TS ID 11933Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer TS ID 11967Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation TSID 12009Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC